Integrated Multi‐Omics and Radiogenomic Analysis Identifies S100B and ITGB5 as Complementary Candidate Biomarkers of Glioblastoma Heterogeneity
Chemical Biology & Drug Design · 2026
DOI: 10.1111/cbdd.70396 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2026. Verfasst von Xuhang Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Glioblastoma, S100 Calcium Binding Protein beta Subunit, Biomarkers, Tumor, Brain Neoplasms. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma (GBM) is characterized by marked intratumoral heterogeneity, diffuse invasion, and a profoundly immunosuppressive tumor microenvironment. In this study, we applied an integrative multi‐omics and radiogenomic framework to identify candidate biomarkers reflecting complementary dimensions of GBM heterogeneity. Public bulk transcriptomic datasets were integrated to define GBM‐related differentially expressed genes, which were intersected with curated microbiota‐associated gene sets as a hypothesis‐generating screening strategy. Machine‐learning models with SHAP interpretation were used for candidate‐gene prioritization, followed by survival‐association analysis, pan‐cancer comparison, Human Protein Atlas immunohistochemistry, CPTAC proteomics, immune infiltration analysis, single‐cell transcriptomics, spatial transcriptomics, in silico perturbation analysis, and MRI‐based radiogenomics. GBM samples showed enrichment of extracellular matrix organization, proliferative programs, immune‐related signaling, and vascular or endothelial pathways, with relative reductions in neural, synaptic, and myelin‐associated signatures. S100B and ITGB5 emerged as survival‐associated candidate markers with different biological contexts. Multi‐omics analyses suggested that S100B may reflect broadly distributed glial‐lineage and malignant‐state programs, whereas ITGB5 was more closely associated with focal extracellular matrix remodeling, stromal‐vascular interactions, and immunoregulatory niches. Radiogenomic analysis further suggested distinct MRI‐derived associations for the two genes, with the ITGB5‐related model retaining a broader radiomic signature and showing a more heterogeneous habitat pattern than the S100B‐related model. These exploratory findings support S100B and ITGB5 as complementary candidate biomarkers of GBM heterogeneity and provide a basis for future experimental, multicenter, and prospective validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wenzhou Medical University, Wenzhou, China.
- Department of Neurosurgery, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- The Key Laboratory of Pediatric Hematology and Oncology Diseases of Wenzhou, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
ORCID-Profile: Xuhang Yang
Zitieren
APA
Yang, X., Zhang, Y., Zheng, Y., & Lin, J. (2026). Integrated Multi‐Omics and Radiogenomic Analysis Identifies S100B and ITGB5 as Complementary Candidate Biomarkers of Glioblastoma Heterogeneity. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70396
Vancouver
Yang X, Zhang Y, Zheng Y, Lin J. Integrated Multi‐Omics and Radiogenomic Analysis Identifies S100B and ITGB5 as Complementary Candidate Biomarkers of Glioblastoma Heterogeneity. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70396
BibTeX
@article{Yang2026,
author = {Yang, Xuhang and Zhang, Yusong and Zheng, Yutuo and Lin, Jian},
title = {Integrated Multi‐Omics and Radiogenomic Analysis Identifies S100B and ITGB5 as Complementary Candidate Biomarkers of Glioblastoma Heterogeneity},
journal = {Chemical Biology & Drug Design},
year = {2026},
doi = {10.1111/cbdd.70396}
}
EUVIMED